{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T03:18:55Z","timestamp":1794712735007,"version":"4.9.1"},"reference-count":113,"publisher":"American Society of Hematology","issue":"13","license":[{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Venetoclax selectively inhibits B-cell lymphoma 2 (BCL-2) and restores apoptotic signaling of hematologic malignant cells. Venetoclax, in combination with hypomethylating and low-dose cytotoxic agents, has revolutionized the management of older patients affected by acute myeloid leukemia (AML) and that of patients unfit to receive intensive chemotherapy. In a single phase 1 pediatric trial conducted on relapsed or refractory AML, the combination of venetoclax and intensive chemotherapy was shown to be safe and yielded promising response rates. In addition, several retrospective studies in children with AML reported that venetoclax, when combined with hypomethylating agents and cytotoxic drugs, seems to be a safe and efficacious bridge to transplant. The promising results on the use of venetoclax combinations in advanced myelodysplastic syndromes (MDS) and therapy-related MDS\/AML have also been reported in small case series. This review summarizes the available current knowledge about venetoclax use in childhood high-risk myeloid neoplasms and discusses the possible integration of BCL-2 inhibition in the current treatment algorithm of these children. It also focuses on specific genetic subgroups potentially associated with response in preclinical and clinical studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023012041","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T15:03:08Z","timestamp":1714748588000},"page":"3583-3595","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":25,"title":["Venetoclax: a new player in the treatment of children with high-risk myeloid malignancies?"],"prefix":"10.1182","volume":"8","author":[{"given":"Riccardo","family":"Masetti","sequence":"first","affiliation":[{"name":"1Pediatric Hematology and Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"},{"name":"2Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8313-7288","authenticated-orcid":false,"given":"Francesco","family":"Baccelli","sequence":"additional","affiliation":[{"name":"1Pediatric Hematology and Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"},{"name":"2Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4673-5876","authenticated-orcid":false,"given":"Davide","family":"Leardini","sequence":"additional","affiliation":[{"name":"1Pediatric Hematology and Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7976-3654","authenticated-orcid":false,"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[{"name":"3Department of Pediatric Hematology and Oncology, Bambino Ges\u00f9 Children\u2019s Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy"},{"name":"4Catholic University of the Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"issue":"1","key":"2024070915211211800_bib1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/cpt.553","article-title":"Targeting BCL2 with BH3 mimetics: basic science and clinical application of venetoclax in chronic lymphocytic leukemia and related B cell malignancies","volume":"101","author":"Roberts","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"2024070915211211800_bib2","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"19","key":"2024070915211211800_bib3","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2024070915211211800_bib4","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Discov"},{"issue":"5712","key":"2024070915211211800_bib5","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1126\/science.1106114","article-title":"Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells","volume":"307","author":"Opferman","year":"2005","journal-title":"Science"},{"issue":"3","key":"2024070915211211800_bib6","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"Bcl-2 inhibitor ABT-263 targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"12","key":"2024070915211211800_bib7","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat Med"},{"issue":"7","key":"2024070915211211800_bib8","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"2024070915211211800_bib9","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"2024070915211211800_bib10","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1182\/bloodadvances.2022007265","article-title":"Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia","volume":"6","author":"Matthews","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"2024070915211211800_bib11","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s12185-023-03533-x","article-title":"Comprehensive molecular understanding of pediatric acute myeloid leukemia","volume":"117","author":"Shiba","year":"2023","journal-title":"Int J Hematol"},{"issue":"2","key":"2024070915211211800_bib12","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/blood-2013-03-491621","article-title":"Results of the AIEOP AML 2002\/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia","volume":"122","author":"Pession","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2024070915211211800_bib13","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.3324\/haematol.2019.220962","article-title":"Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children\u2019s Oncology Group","volume":"105","author":"Aplenc","year":"2020","journal-title":"Haematologica"},{"issue":"4","key":"2024070915211211800_bib14","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/bjh.13611","article-title":"Outcome of children with acute myeloid leukaemia (AML) experiencing primary induction failure in the AIEOP AML 2002\/01 clinical trial","volume":"171","author":"Quarello","year":"2015","journal-title":"Br J Haematol"},{"issue":"27","key":"2024070915211211800_bib15","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1200\/JCO.2015.62.8289","article-title":"Collaborative efforts driving progress in pediatric acute myeloid leukemia","volume":"33","author":"Zwaan","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2024070915211211800_bib16","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.2012.43.7384","article-title":"Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the international BFM study group","volume":"31","author":"Kaspers","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024070915211211800_bib17","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3324\/haematol.2018.191841","article-title":"Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-M\u00fcnster study group","volume":"104","author":"Niktoreh","year":"2019","journal-title":"Haematologica"},{"issue":"3","key":"2024070915211211800_bib18","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/bjh.14247","article-title":"Whole-exome sequencing reveals the spectrum of gene mutations and the clonal evolution patterns in paediatric acute myeloid leukaemia","volume":"175","author":"Shiba","year":"2016","journal-title":"Br J Haematol"},{"issue":"9","key":"2024070915211211800_bib19","first-page":"2275","article-title":"Relapsed pediatric acute myeloid leukaemia: state-of-the-art in 2023","volume":"108","author":"Egan","year":"2023","journal-title":"Haematologica"},{"issue":"19","key":"2024070915211211800_bib20","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1200\/JCO.19.03306","article-title":"Phase I\/II study of CPX-351 followed by fludarabine, cytarabine, and granulocyte-colony stimulating factor for children with relapsed acute myeloid leukemia: a report from the children\u2019s oncology group","volume":"38","author":"Cooper","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"2024070915211211800_bib21","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/bloodadvances.2019000357","article-title":"Opportunities for immunotherapy in childhood acute myeloid leukemia","volume":"3","author":"Lamble","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"2024070915211211800_bib22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13045-022-01376-3","article-title":"Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia","volume":"15","author":"Caruso","year":"2022","journal-title":"J\u00a0Hematol Oncol"},{"issue":"35","key":"2024070915211211800_bib23","doi-asserted-by":"crossref","first-page":"56746","DOI":"10.18632\/oncotarget.10778","article-title":"Genomic complexity and dynamics of clonal evolution in childhood acute myeloid leukemia studied with whole-exome sequencing","volume":"7","author":"Masetti","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"2024070915211211800_bib24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nm.4439","article-title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions","volume":"24","author":"Bolouri","year":"2018","journal-title":"Nat Med"},{"issue":"23","key":"2024070915211211800_bib25","doi-asserted-by":"crossref","first-page":"16708","DOI":"10.3390\/ijms242316708","article-title":"Recent updates in venetoclax combination therapies in pediatric hematological malignancies","volume":"24","author":"Le\u015bniak","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2024070915211211800_bib26","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S1470-2045(20)30060-7","article-title":"Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study","volume":"21","author":"Karol","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10","key":"2024070915211211800_bib27","doi-asserted-by":"crossref","first-page":"e28398","DOI":"10.1002\/pbc.28398","article-title":"Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia","volume":"67","author":"Winters","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2024070915211211800_bib28","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3390\/children10040745","article-title":"Venetoclax use in paediatric haemato-oncology centres in Poland: a 2022 survey","volume":"10","author":"Bobeff","year":"2023","journal-title":"Children"},{"issue":"6","key":"2024070915211211800_bib29","doi-asserted-by":"crossref","first-page":"e30335","DOI":"10.1002\/pbc.30335","article-title":"Venetoclax in combination with chemotherapy as treatment for pediatric advanced hematologic malignancies","volume":"70","author":"Marinoff","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2024070915211211800_bib30","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/S2666-6367(22)00309-8","article-title":"Venetoclax-based combination therapy as a bridge to allogeneic hematopoietic stem cell transplant in children with relapsed\/refractory AML","volume":"28","author":"Pfeiffer","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"16","key":"2024070915211211800_bib31","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1182\/bloodadvances.2023010113","article-title":"Venetoclax-based therapies in pediatric advanced MDS and relapsed\/refractory AML: a multicenter retrospective analysis","volume":"7","author":"Masetti","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"2024070915211211800_bib32","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.3390\/cancers15071983","article-title":"Venetoclax for acute myeloid leukemia in pediatric patients: a Texas Medical Center experience","volume":"15","author":"Trabal","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"11","key":"2024070915211211800_bib33","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.3324\/haematol.2022.282637","article-title":"Clinical responses in pediatric patients with relapsed\/refractory leukemia treated with azacitidine and venetoclax","volume":"108","author":"Niswander","year":"2023","journal-title":"Haematologica"},{"issue":"7","key":"2024070915211211800_bib34","doi-asserted-by":"crossref","first-page":"e30308","DOI":"10.1002\/pbc.30308","article-title":"Combined treatment with venetoclax, dasatinib, and FLT3 inhibitors for NUP98-NSD1+\/FLT3-ITD+ acute myeloid leukemia: a pediatric case report","volume":"70","author":"Wen","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2024070915211211800_bib35","doi-asserted-by":"crossref","first-page":"e30021","DOI":"10.1002\/pbc.30021","article-title":"Refractory pediatric acute myeloid leukemia expressing NUP98-NSD1 fusion gene responsive to chemotherapy combined with venetoclax and decitabine","volume":"70","author":"Xu","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"2024070915211211800_bib36","doi-asserted-by":"crossref","first-page":"e29678","DOI":"10.1002\/pbc.29678","article-title":"Ex\u00a0vivo drug sensitivity profiling-guided treatment of a relapsed pediatric mixed-phenotype acute leukemia with venetoclax and azacitidine","volume":"69","author":"Gonzales","year":"2022","journal-title":"Pediatr Blood Cancer"},{"issue":"22","key":"2024070915211211800_bib37","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.1158\/1078-0432.CCR-19-0832","article-title":"Inhibition of Bcl-2 synergistically enhances the antileukemic activity of midostaurin and gilteritinib in preclinical models of FLT3-mutated acute myeloid leukemia","volume":"25","author":"Ma","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"15","key":"2024070915211211800_bib38","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1002\/cncr.33531","article-title":"Activity of venetoclax against relapsed acute undifferentiated leukemia","volume":"127","author":"Caldwell","year":"2021","journal-title":"Cancer"},{"issue":"3","key":"2024070915211211800_bib40","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00277-023-05083-y","article-title":"Molecular complete remission following combination treatment of daratumumab and venetoclax in an adolescent with relapsed mixed phenotype acute leukemia","volume":"102","author":"Stanulla","year":"2023","journal-title":"Ann Hematol"},{"issue":"3","key":"2024070915211211800_bib41","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000524182","article-title":"The clinical tumor lysis syndrome in a patient with mixed phenotype acute leukemia undergoing induction with venetoclax and azacitidine: a case report","volume":"67","author":"Drozd-Sokolowska","year":"2022","journal-title":"Chemotherapy"},{"issue":"11","key":"2024070915211211800_bib42","doi-asserted-by":"crossref","first-page":"e30597","DOI":"10.1002\/pbc.30597","article-title":"Case report: positive response to venetoclax and azacitidine in the treatment of acute myeloid leukemia with myelodysplasia-related changes and blasts of the mixed T\/myeloid phenotype","volume":"70","author":"Wen","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2024070915211211800_bib43","doi-asserted-by":"crossref","first-page":"127.e1","DOI":"10.1016\/j.jtct.2022.11.022","article-title":"Targeted therapy with venetoclax and daratumumab as part of HSCT preparative regimen in children with\u00a0chemorefractory acute myeloid leukemia","volume":"29","author":"Klimentova","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"2024070915211211800_bib44","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00428-022-03447-9","article-title":"The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia","volume":"482","author":"Rudelius","year":"2023","journal-title":"Virchows Arch"},{"issue":"11","key":"2024070915211211800_bib45","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2024070915211211800_bib46","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2141.2011.08724.x","article-title":"Advances in the prognostication and management of advanced MDS in children","volume":"154","author":"Hasle","year":"2011","journal-title":"Br J Haematol"},{"issue":"13","key":"2024070915211211800_bib47","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/blood-2017-09-765214","article-title":"How I treat myelodysplastic syndromes of childhood","volume":"131","author":"Locatelli","year":"2018","journal-title":"Blood"},{"issue":"10","key":"2024070915211211800_bib48","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1038\/s41591-021-01511-6","article-title":"Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9\/SAMD9L syndromes","volume":"27","author":"Sahoo","year":"2021","journal-title":"Nat Med"},{"issue":"11","key":"2024070915211211800_bib49","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1182\/blood-2015-09-669937","article-title":"Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents","volume":"127","author":"Wlodarski","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2024070915211211800_bib50","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/sj.leu.2402271","article-title":"Myelodysplastic syndrome in childhood: a retrospective study of 189 patients in Japan","volume":"15","author":"Sasaki","year":"2001","journal-title":"Leukemia"},{"issue":"2","key":"2024070915211211800_bib51","first-page":"434","article-title":"Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children\u2019s Cancer Group","volume":"20","author":"Woods","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024070915211211800_bib52","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/pbc.25238","article-title":"Allogeneic hematopoietic stem cell transplantation in pediatric myelodysplastic syndromes: a multicenter experience from Argentina","volume":"62","author":"Basquiera","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"20","key":"2024070915211211800_bib53","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2024070915211211800_bib54","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/leu.2010.297","article-title":"Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study","volume":"25","author":"Strahm","year":"2011","journal-title":"Leukemia"},{"key":"2024070915211211800_bib55","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-3152660\/v1","article-title":"Disease burden at time of transplant is a primary predictor of outcomes in pediatric MDS: a single center experience","author":"Dahlberg","year":"13  2023","journal-title":"Research Square"},{"issue":"9","key":"2024070915211211800_bib56","doi-asserted-by":"crossref","first-page":"e30530","DOI":"10.1002\/pbc.30530","article-title":"Impact of cytoreduction and remission status on hematopoietic cell transplantation outcomes in pediatric myelodysplastic syndrome and related disorders","volume":"70","author":"Wachter","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2024070915211211800_bib57","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/bloodadvances.2021006139","article-title":"CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies","volume":"6","author":"Hu","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2024070915211211800_bib58","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/s12887-022-03376-1","article-title":"The effect of decitabine-combined minimally myelosuppressive regimen bridged allo-HSCT on the outcomes of pediatric MDS from 10 years\u2019 experience of a single center","volume":"22","author":"Gao","year":"2022","journal-title":"BMC Pediatr"},{"issue":"6","key":"2024070915211211800_bib59","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/bjh.13915","article-title":"Therapy with low-dose azacitidine for MDS in children and young adults: a retrospective analysis of the EWOG-MDS study group","volume":"172","author":"Cseh","year":"2016","journal-title":"Br J Haematol"},{"issue":"5","key":"2024070915211211800_bib60","doi-asserted-by":"crossref","first-page":"e30931","DOI":"10.1002\/pbc.30931","article-title":"Efficacy and safety of azacitidine in pediatric patients with newly diagnosed advanced myelodysplastic syndromes before hematopoietic stem cell transplantation in the AZA-JMML-001 trial","volume":"71","author":"Locatelli","year":"2024","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2024070915211211800_bib61","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/ajh.26771","article-title":"A\u00a0phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes","volume":"98","author":"Zeidan","year":"2023","journal-title":"Am J Hematol"},{"issue":"6","key":"2024070915211211800_bib62","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1111\/bjh.16682","article-title":"Venetoclax and decitabine for relapsed paediatric myelodysplastic syndrome-related acute myeloid leukaemia with complex aberrant karyotype after second stem cell transplantation","volume":"189","author":"Raedler","year":"2020","journal-title":"Br J Haematol"},{"key":"2024070915211211800_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fped.2022.1059569","article-title":"Case report: venetoclax therapy in a boy with acute myeloid leukemia in Shwachman Diamond syndrome","volume":"10","author":"Naviglio","year":"2023","journal-title":"Front Pediatr"},{"key":"2024070915211211800_bib64","doi-asserted-by":"crossref","first-page":"e2200693","DOI":"10.1200\/PO.22.00693","article-title":"Venetoclax and azacitidine in the treatment of NPM1-mutated donor cell\u2013derived leukemia in a patient with Fanconi anemia: case report and literature review","volume":"7","author":"Ma","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"10","key":"2024070915211211800_bib65","doi-asserted-by":"crossref","first-page":"e28652","DOI":"10.1002\/pbc.28652","article-title":"Diagnosis and treatment of pediatric myelodysplastic syndromes: a survey of the North American Pediatric Aplastic Anemia Consortium","volume":"67","author":"Nakano","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"16","key":"2024070915211211800_bib66","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.22.02120","article-title":"Measurable residual disease and fusion partner independently predict survival and relapse risk in childhood KMT2A-rearranged acute myeloid leukemia: a study by the International Berlin-Frankfurt-M\u00fcnster Study Group","volume":"41","author":"Van Weelderen","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2024070915211211800_bib67","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/s41375-023-01877-1","article-title":"The KMT2A recombinome of acute leukemias in 2023","volume":"37","author":"Meyer","year":"2023","journal-title":"Leukemia"},{"issue":"7954","key":"2024070915211211800_bib68","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"issue":"1","key":"2024070915211211800_bib69","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41375-022-01746-3","article-title":"Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy","volume":"37","author":"Cheung","year":"2023","journal-title":"Leukemia"},{"issue":"13","key":"2024070915211211800_bib70","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1080\/10428194.2022.2116934","article-title":"Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-rearranged acute myeloid leukemia (AML)","volume":"63","author":"Ball","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"suppl 1","key":"2024070915211211800_bib71","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2023-182337","article-title":"Early results of the phase I\/II study investigating the all-oral combination of the menin inhibitor revumenib (SNDX-5613) with decitabine\/cedazuridine (ASTX727) and venetoclax in acute myeloid leukemia (SAVE)","volume":"142","author":"Issa","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2024070915211211800_bib72","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41408-021-00603-3","article-title":"Effective menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)","volume":"12","author":"Fiskus","year":"2022","journal-title":"Blood Cancer J"},{"key":"2024070915211211800_bib73","doi-asserted-by":"crossref","first-page":"820191","DOI":"10.3389\/fphar.2021.820191","article-title":"Novel compounds synergize with venetoclax to target KMT2A-rearranged pediatric acute myeloid leukemia","volume":"12","author":"Tregnago","year":"2021","journal-title":"Front Pharmacol"},{"issue":"12","key":"2024070915211211800_bib74","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1182\/blood-2006-03-009233","article-title":"Clinical implications of FLT3 mutations in pediatric AML","volume":"108","author":"Meshinchi","year":"2006","journal-title":"Blood"},{"issue":"24","key":"2024070915211211800_bib75","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1200\/JCO.2011.34.7427","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed\/refractory leukemia","volume":"29","author":"Inaba","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"2024070915211211800_bib76","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-15-1998","article-title":"A\u00a0phase I study of quizartinib combined with chemotherapy in relapsed childhood leukemia: a Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) study","volume":"22","author":"Cooper","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2024070915211211800_bib77","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","article-title":"Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study","volume":"18","author":"Perl","year":"2017","journal-title":"Lancet Oncol"},{"issue":"3","key":"2024070915211211800_bib78","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bjh.15725","article-title":"CBFA2T3-GLIS2-positive acute myeloid leukaemia. A peculiar paediatric entity","volume":"184","author":"Masetti","year":"2019","journal-title":"Br J Haematol"},{"issue":"22","key":"2024070915211211800_bib79","doi-asserted-by":"crossref","first-page":"e157101","DOI":"10.1172\/JCI157101","article-title":"CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target","volume":"132","author":"Le","year":"2022","journal-title":"J\u00a0Clin Invest"},{"issue":"suppl 1","key":"2024070915211211800_bib80","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood-2022-162842","article-title":"Anti-leukemic activity of STRO-002 a novel folate receptor-\u03b1 (FR-\u03b1)-targeting ADC in relapsed\/refractory CBF2AT3-GLIS2 AML","volume":"140","author":"Meshinchi","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2024070915211211800_bib81","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/pbc.29221","article-title":"Azacitidine and venetoclax for post-transplant relapse in a case of CBFA2T3\/GLIS2 childhood acute myeloid leukaemia","volume":"68","author":"Mishra","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2024070915211211800_bib82","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41375-022-01800-0","article-title":"High caspase 3 and vulnerability to dual BCL2 family inhibition define ETO2::GLIS2 pediatric leukemia","volume":"37","author":"Aid","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"2024070915211211800_bib83","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/bloodadvances.2022008899","article-title":"CBFA2T3::GLIS2 pediatric acute megakaryoblastic leukemia is sensitive to BCL-XL inhibition by navitoclax and DT2216","volume":"8","author":"Gress","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"2024070915211211800_bib84","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-I, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2024070915211211800_bib85","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm.3788","article-title":"Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia","volume":"21","author":"Chan","year":"2015","journal-title":"Nat Med"},{"issue":"10","key":"2024070915211211800_bib86","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/leu.2011.133","article-title":"IDH1 and IDH2 mutations in pediatric acute leukemia","volume":"25","author":"Andersson","year":"2011","journal-title":"Leukemia"},{"issue":"2","key":"2024070915211211800_bib87","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/leu.2008.313","article-title":"Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML","volume":"23","author":"Hollink","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"2024070915211211800_bib88","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/2159-8290.CD-22-0366","article-title":"Mutant NPM1 directly regulates oncogenic transcription in acute myeloid leukemia","volume":"13","author":"Uckelmann","year":"2023","journal-title":"Cancer Discov"},{"issue":"6","key":"2024070915211211800_bib89","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/bloodadvances.2022008316","article-title":"Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML","volume":"7","author":"Issa","year":"2023","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2024070915211211800_bib90","doi-asserted-by":"crossref","first-page":"100071","DOI":"10.1016\/j.ejcped.2023.100071","article-title":"P6 - NPM1 mutations in children with myelodysplastic syndrome with excess blasts","volume":"2","author":"Yoshimi","year":"2023","journal-title":"EJC Paediatric Oncology"},{"issue":"20","key":"2024070915211211800_bib91","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1002\/cncr.33689","article-title":"Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax","volume":"127","author":"Kim","year":"2021","journal-title":"Cancer"},{"issue":"suppl 1","key":"2024070915211211800_bib92","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1182\/blood-2018-99-119806","article-title":"PTPN11 mutations confer unique metabolic properties and increase resistance to venetoclax and azacitidine in acute myelogenous leukemia","volume":"132","author":"Stevens","year":"2018","journal-title":"Blood"},{"key":"2024070915211211800_bib93","doi-asserted-by":"crossref","first-page":"115705","DOI":"10.1016\/j.bcp.2023.115705","article-title":"Pediatric acute myeloid leukemia: insight into genetic landscape and novel targeted approaches","volume":"215","author":"Tosic","year":"2023","journal-title":"Biochem Pharmacol"},{"issue":"23","key":"2024070915211211800_bib94","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.3390\/cancers15235594","article-title":"Development of MDS in pediatric patients with GATA2 deficiency: increased histone trimethylation and deregulated apoptosis as potential drivers of transformation","volume":"15","author":"Schreiber","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"suppl 2","key":"2024070915211211800_bib95","article-title":"Integrated genomic analysis identifies UBTF tandem duplications as a subtype-defining lesion in pediatric acute myeloid leukemia","volume":"138","author":"Umeda","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2024070915211211800_bib96","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/s41375-023-01906-z","article-title":"UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia","volume":"37","author":"Duployez","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"2024070915211211800_bib97","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41408-023-00858-y","article-title":"UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome","volume":"13","author":"Georgi","year":"2023","journal-title":"Blood Cancer J"},{"issue":"suppl 1","key":"2024070915211211800_bib98","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1182\/blood-2022-159002","article-title":"UBTF tandem duplications account for a third of advanced pediatric MDS without genetic predisposition to myeloid neoplasia","volume":"140","author":"Erlacher","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2024070915211211800_bib99","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.2023021359","article-title":"Acute myeloid leukemias with UBTF tandem duplications are sensitive to Menin inhibitors","volume":"143","author":"Barajas","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2024070915211211800_bib100","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/leu.2016.222","article-title":"HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia","volume":"31","author":"Kontro","year":"2017","journal-title":"Leukemia"},{"key":"2024070915211211800_bib101","doi-asserted-by":"crossref","first-page":"100093","DOI":"10.1016\/j.ejcped.2023.100093","article-title":"Relapsed UBTF-TD MDS treated with venetoclax and azacitidine","volume":"2","author":"Hasle","year":"2023","journal-title":"EJC Paediatr Oncol"},{"issue":"suppl 15","key":"2024070915211211800_bib102","doi-asserted-by":"crossref","first-page":"TPS7052","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS7052","article-title":"V2 Trial: a phase I study of venetoclax and CPX-351 for young patients with relapsed\/refractory acute leukemia","volume":"39","author":"Agresta","year":"2021","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2024070915211211800_bib103","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1182\/blood-2022-168818","article-title":"ITCC-101\/APAL2020D: a randomized phase 3 trial of fludarabine\/cytarabine\/gemtuzumab ozogamycin with or without venetoclax in children with relapsed acute myeloid leukemia","volume":"140","author":"Ishimaru","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2024070915211211800_bib104","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1111\/bjh.18936","article-title":"Successful treatment of a chemotherapy-resistant t(17;19) paediatric ALL with a combination of inotuzumab, venetoclax and navitoclax","volume":"202","author":"Gottardi","year":"2023","journal-title":"Br J Haematol"},{"issue":"9","key":"2024070915211211800_bib105","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.3324\/haematol.2019.222588","article-title":"Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia","volume":"104","author":"Tausch","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"2024070915211211800_bib106","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","article-title":"Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"suppl 1","key":"2024070915211211800_bib107","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1182\/blood-2023-185621","article-title":"Acquired venetoclax resistance in an in\u00a0vivo model of B-cell precursor acute lymphoblastic leukemia is characterized by altered functions of apoptosis regulators","volume":"142","author":"Enzenm\u00fcller","year":"2023","journal-title":"Blood"},{"issue":"6","key":"2024070915211211800_bib108","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1158\/2643-3230.BCD-23-0014","article-title":"Clinical correlates of venetoclax-based combination sensitivities to augment acute myeloid leukemia therapy","volume":"4","author":"Eide","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"2024070915211211800_bib109","doi-asserted-by":"crossref","first-page":"115981","DOI":"10.1016\/j.bcp.2023.115981","article-title":"Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and\/or purine biosynthesis in vitro","volume":"220","author":"Hurrish","year":"2024","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"2024070915211211800_bib110","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3892\/etm.2023.12274","article-title":"Glutathione promotes the synergistic effects of venetoclax and azacytidine against myelodysplastic syndrome-refractory anemia by regulating the cell cycle","volume":"26","author":"Wang","year":"2023","journal-title":"Exp Ther Med"},{"issue":"2","key":"2024070915211211800_bib111","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41408-021-00410-w","article-title":"Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia","volume":"11","author":"Maiti","year":"2021","journal-title":"Blood Cancer J"},{"issue":"14","key":"2024070915211211800_bib112","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.3390\/cancers14143456","article-title":"Targeting acute myeloid leukemia with venetoclax; biomarkers for sensitivity and rationale for venetoclax-based combination therapies","volume":"14","author":"Griffioen","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2024070915211211800_bib113","doi-asserted-by":"crossref","first-page":"e28865","DOI":"10.1002\/pbc.28865","article-title":"Venetoclax\/decitabine for a pediatric patient with chronic myelomonocytic leukemia","volume":"68","author":"Molina","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2024070915211211800_bib114","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41375-023-02079-5","article-title":"BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia","volume":"38","author":"Wu","year":"2024","journal-title":"Leukemia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/13\/3583\/2233858\/blooda_adv-2023-012041-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/13\/3583\/2233858\/blooda_adv-2023-012041-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T12:37:01Z","timestamp":1720528621000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/13\/3583\/516002\/Venetoclax-a-new-player-in-the-treatment-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":113,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,7,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012041","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]}}}